Single Loop DJB Sleeve Gastrectomy for Poorly Controlled T2DM

NCT ID: NCT03125369

Last Updated: 2017-04-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-31

Study Completion Date

2018-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Type 2 diabetes mellitus (T2DM) is a chronic progressive illness affecting a substantial percentage of the general population. While pharmacotherapy remains the mainstay of treatment, around 60% of patients cannot achieve the recommended goals for diabetic control. Weight control is a well-known essential component in normalizing blood glucose level in T2DM. The term metabolic surgery is recently introduced and it is now increasingly accepted as a valid option for obese T2DM patients with poor glycemic control despite optimal medical therapy. While laparoscopic roux-en-Y gastric bypass (RYGBP) is the gold-standard bariatric/metabolic procedure in many countries, it is not widely accepted in Asia. Recently, a novel bypass technique called single loop duodenojejunal bypass with sleeve gastrectomy (SLDJB-SG) has been developed trying to tackle most drawbacks of RYGBP. Realizing there is a knowledge gap in applying the new duodenojejunal bypass procedure to obese T2DM patients, we propose to investigate and compare the efficacy of glycemic control and functional outcomes of SLDJB-SG with conventional RYGBP.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aim of study:

To investigate and compare the safety profile, functional outcomes, efficacy in diabetic control and changes of hormonal profile of laparoscopic single loop duodenojejunal bypass plus sleeve gastrectomy (SLDJB-SG) versus the conventional standard roux-en-Y gastric bypass (RYGBP).

Hypothesis:

The efficacy of glycemic control and functional outcomes of SLDJB-SG is better than conventional RYGBP, and is a more suitable option for obese Chinese diabetic patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus Obesity Bariatric Surgery Candidate Weight Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Duodenojejunal bypass

patients receive sleeve gastrectomy plus duodeno-jejunal bypass

Group Type EXPERIMENTAL

Sleeve gastrectomy + duodeno-jejunal bypass

Intervention Type PROCEDURE

Roux-en-Y gastric bypass

patients receive roux-Y gastric bypass

Group Type ACTIVE_COMPARATOR

Roux-Y gastric bypass

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sleeve gastrectomy + duodeno-jejunal bypass

Intervention Type PROCEDURE

Roux-Y gastric bypass

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* aged between 20 to 65 years
* at least 2 years of T2DM
* a BMI between 28 to 42 kg/m2
* a HbA1c level above 7% despite multiple oral medications (\> 2) at higher than or equal to half-maximal dose, or already using insulin injection for more than 6 months
* no active cardiovascular diseases, and
* a ASA grade II or below
* a fasting C-peptide \< 0.6ug/L

Exclusion Criteria

* significant anaesthetic risk ASA grade III or above
* history of diabetic ketoacidosis
* uncontrolled DM with HbA1c \> 12%
* malignancy diagnosed within 5 years
* chronic renal failure requiring dialysis
* previous upper abdominal surgery affecting gastroduodenal configuration
* major psychiatric illness including major depression and substance abuse
* pregnancy or ongoing breast-feeding
* inmates
Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chinese University of Hong Kong

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Enders K.W. Ng

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Enders KW Ng, Professor

Role: PRINCIPAL_INVESTIGATOR

Chinese University of Hong Kong

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chinese University of Hong Kong

Hong Kong, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Enders Ng, MD

Role: CONTACT

+852 26322956

Candice Lam, BN

Role: CONTACT

+852 26322956

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Enders Ng, MD

Role: primary

+852 26322956

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SLDJBSG_DM

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.